The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Fraxinus Excelsior and Vitamin E Combination for NAFLD (FEVEN)


Affiliations
1 Medical Affairs Department, Macleods Pharmaceuticals Ltd.
     

   Subscribe/Renew Journal


Objective: The combination of Vitamin E 400 IU soft gelatin capsule and Fraxinus excelsior500 mg soft gelatin capsules (Ensules+) were evaluated for safety and efficacy as compared to Vitamin E 400 IU soft gelatin capsules in patients with NAFLD.

Material and Methods: The prospective, open-label, comparative, randomized, single centre clinical trial was conducted by Macleods Pharmaceuticals in collaboration with Muktai Hospital, Nashik. Total of 24 NAFLD patients were divided into 2 groups and received either Vitamin E (400 IU) soft gelatin capsule or Ensules+ (combination of Vitamin E 400 IU and Fraxinus excelsior 500mg) soft gelatin capsules BID for 8 weeks. The Grades of Liver steatosis after 8 weeks, liver function test (AST, ALT, ALP, bilirubin levels) and serum lipid profile (Tg, Tc, HDL, LDL) was evaluated at the end of the study.

Result: Nonalcoholic fatty liver disease (NAFLD) patients with Vitamin E and Ensules+ therapy BID for 8 weeks revealed no significant difference in the physical parameters like mean body temperature, pulse rate and blood pressure from baseline to end of the study.

Significant improvement in lipid profile and liver function parameters were observed in both the groups at the end of the study as compared to the baseline. The % improvement in Tc and LDL (3.27 % and 4.93% respectively) from baseline were significant in Ensules+ group (B) as compared to Vitamin E group (A) (1.10% and 1.13 % respectively), also HDL levels were significantly elevated (1.34 %) in Ensules+ group.

Percentage improvement in liver function parameters in group A patients treated with Ensules+ Capsule had higher AST (53.64%), ALT (59.53%) ALP (38.43%) and Bilirubin levels (56.54%) as compared to group B patients treated with vitamin E capsules.

5 Patients treated with Ensules+ (combination of Vitamin E 400IU and Fraxinus excelsior 500mg) soft gelatin capsules) showed significant regression with the fatty liver disease at the end of the study.

Conclusion: Combination of Vitamin E and Fraxinus excelsior (Ensules+) capsule were found to be better in improving the lipid profile and liver function parameters in patients with NAFLD. To the best of our knowledge, this is the first study which compares the combination with Vitamin E capsule and found to be more effective in treating patients with NAFLD.


Keywords

NAFLD, NASH, Vitamin E, Fraxinus Excelsior, Ensules+
Subscription Login to verify subscription
User
Notifications
Font Size


  • Ashtari S, Purhoseingholi MA, Zali MR. Non-alcohol fatty liver disease in Asia: Prevention and planning. World J Hepatol. 2015; 7(13): 1788–1796.

  • Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India. 2013 Jul;61(7):44853.

  • Patell R, Dosi R, Joshi H, Sheth S, Shah P, Jasdanwala S, et al. Non-Alcoholic Fatty Liver Disease (NAFLD) in Obesity. J ClinDiagn Res. 2014; 8(1): 62–66.

  • Pacana T, Sanyal AJ. Vitamin E and Non-alcoholic Fatty Liver Disease. CurrOpinClinNutrMetab Care. 2012; 15(6): 641–648.

  • Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. Q J Med. 2010; 103:71–83.

  • M. Eddouks M et al. Phlorizin-like effect of Fraxinus excelsior in normal and diabetic rats. Journal of Ethnopharmacology. 2004; 149–154.

  • NaishengBai, et al. Iridoids from Fraxinus excelsior with Adipocyte Differentiation-Inhibitory and PPARr Activation Activity. J. Nat. Prod. 2010; (73): 2–6.

  • Thomas Ughetto. Glucevia Fraxinus excelsior Extract Effectively Controls Blood Glucose Levels in Randomized, Controlled Trial. Integr Med (Encinitas). 2014; 13(4): 30–32.

  • Kratz A, Sluss PM, Januzzi JL., Jr. Appendices: Laboratory values of clinical importance. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, editors. Harrison’s Principles of Internal Medicine. 16th ed. The United States of America: The McGraw-Hill Companies, Inc.; 2005: A1–7.

  • Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 2010; 362:167585.

  • Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Nutrition. 2015; 31: 923–930.

  • Zulet MA, Carretero SN, Sánchez DL, Abete I, Flanagan J, Issaly N, Berthon PF, et al. A Fraxinus excelsior L. seeds/ fruits extract benefits glucose Homeostasis and adiposity related markers in elderly overweight/obese subjects: A longitudinal, randomized, crossover, double-blind, placebocontrolled nutritional intervention study. Phytomedicine. 2014; 2: 1162–1169.


Abstract Views: 258

PDF Views: 0




  • Fraxinus Excelsior and Vitamin E Combination for NAFLD (FEVEN)

Abstract Views: 258  |  PDF Views: 0

Authors

Sachin Kadoo
Medical Affairs Department, Macleods Pharmaceuticals Ltd.
Soumen Roy
Medical Affairs Department, Macleods Pharmaceuticals Ltd.
Naveen Parmar
Medical Affairs Department, Macleods Pharmaceuticals Ltd.

Abstract


Objective: The combination of Vitamin E 400 IU soft gelatin capsule and Fraxinus excelsior500 mg soft gelatin capsules (Ensules+) were evaluated for safety and efficacy as compared to Vitamin E 400 IU soft gelatin capsules in patients with NAFLD.

Material and Methods: The prospective, open-label, comparative, randomized, single centre clinical trial was conducted by Macleods Pharmaceuticals in collaboration with Muktai Hospital, Nashik. Total of 24 NAFLD patients were divided into 2 groups and received either Vitamin E (400 IU) soft gelatin capsule or Ensules+ (combination of Vitamin E 400 IU and Fraxinus excelsior 500mg) soft gelatin capsules BID for 8 weeks. The Grades of Liver steatosis after 8 weeks, liver function test (AST, ALT, ALP, bilirubin levels) and serum lipid profile (Tg, Tc, HDL, LDL) was evaluated at the end of the study.

Result: Nonalcoholic fatty liver disease (NAFLD) patients with Vitamin E and Ensules+ therapy BID for 8 weeks revealed no significant difference in the physical parameters like mean body temperature, pulse rate and blood pressure from baseline to end of the study.

Significant improvement in lipid profile and liver function parameters were observed in both the groups at the end of the study as compared to the baseline. The % improvement in Tc and LDL (3.27 % and 4.93% respectively) from baseline were significant in Ensules+ group (B) as compared to Vitamin E group (A) (1.10% and 1.13 % respectively), also HDL levels were significantly elevated (1.34 %) in Ensules+ group.

Percentage improvement in liver function parameters in group A patients treated with Ensules+ Capsule had higher AST (53.64%), ALT (59.53%) ALP (38.43%) and Bilirubin levels (56.54%) as compared to group B patients treated with vitamin E capsules.

5 Patients treated with Ensules+ (combination of Vitamin E 400IU and Fraxinus excelsior 500mg) soft gelatin capsules) showed significant regression with the fatty liver disease at the end of the study.

Conclusion: Combination of Vitamin E and Fraxinus excelsior (Ensules+) capsule were found to be better in improving the lipid profile and liver function parameters in patients with NAFLD. To the best of our knowledge, this is the first study which compares the combination with Vitamin E capsule and found to be more effective in treating patients with NAFLD.


Keywords


NAFLD, NASH, Vitamin E, Fraxinus Excelsior, Ensules+

References